[elfsight_social_share_buttons id=”1″]

The FDA has approved the first oral drug meant to treat postpartum depression.

The antidepressant, known as Zurzuvae, can now be prescribed in order to treat PPD, which affects about half a million women in the U.S. today. The drug is meant to be good news for moms and their babies alike, since the mother-infant bond is crucial for the healthy development of children.

Compared to other PPD treatments, Zurzuvae is a once-a-day, rapid-acting drug meant to be taken for 14 days. It’s expected to available later this year.